Small cell lung cancer (sclc) is a highly malignant tumor. It has unique and recalcitrant lung cancer symptoms. In recent years, due to the continuous innovation of chemotherapeutic drugs, protocols and methods, chemotherapy-based multidisciplinary treatment has made great progress in sclc, and the long-term survival rate has improved more than before. The most effective treatment option for limited stage (ld) sclc is pe (cisplatin + vp16) synchronized with brain radiotherapy (trt). Surgery also prolongs the survival and survival of patients with sclc. Because most patients are diagnosed with lymph node or distant metastases and have no symptoms of surgically treated lung cancer, staging of small cell lung cancer is rarely done using TNM staging, but is simply divided into limited and extensive stages based on the extent of the lesion. Unfavorable prognostic factors include extensive stage disease, elevated LDH values, poor behavioral status score weight loss, and male gender. Treatment of limited-stage small cell lung cancer should be a 4- to 6-cycle EP regimen [(etoposide VP-16) + cisplatin (DDP)] chemotherapy combined with concurrent chest radiation. In extensive disease, systemic chemotherapy is the mainstay, and the regimen is mostly VP-16 combined with cisplatin or carboplatin. Combination chemotherapy is recommended even for older patients or those with poor behavioral status scores. Small cell lung cancer must be treated mainly with systemic chemotherapy, together with herbal medicine to reduce the toxic side effects of the replacement agent and increase the effectiveness of chemotherapy. Because small cell lung cancer has poor biological behavior, fast growth, short doubling time (21 -30 days for tumor to double in size), high malignancy, and rapid and extensive metastasis. At the time of diagnosis, about 90% of the patients have intra-thoracic and potential distant micrometastases, the most common of which are mediastinal metastases, followed by liver, bone, bone marrow, brain and other distant metastases, so systemic treatment should be the main focus. The order and importance of chemotherapy in the comprehensive treatment should be different for each stage of small cell lung cancer due to the different lesion scope and location. In stage IV, chemotherapy should be the main treatment, and in chemotherapy, metastases such as bone metastases should be treated with palliative radiotherapy or liver metastases should be treated with intervention according to specific conditions. In order to overcome drug resistance in stage N small cell lung cancer, alternating chemotherapy has been randomly used to compare with a single chemotherapy regimen, with only a slight improvement in median survival (4 – 6 weeks) and the advantage of long-term survival for the former. However, it is still controversial whether this treatment is better than conventional chemotherapy, and it is expensive, so it is not recommended for routine use. Stage IIB or IV lung cancer that cannot be resected radically by surgery should be treated with induction chemotherapy (neoadjuvant chemotherapy) followed by local radiotherapy (sequential therapy), which has long been proven to be wrong, except for certain specific syndromes such as superior vena cava syndrome, where radiotherapy can be effective. The complementary efficacy of concurrent chemotherapy and radiotherapy (simultaneous control of intrathoracic lesions and distant micrometastases) for limited-stage small cell lung cancer has been widely appreciated and recognized. However, the optimal dose of radiotherapy and chemotherapy drug dose remain to be solved. For patients who are too old and frail for radiotherapy, conservative treatment with Chinese medicine is recommended. Adjuvant chemotherapy should be administered immediately after surgery, and stage III (mediastinal lymph node metastasis) resectable patients should also be treated with preoperative chemotherapy (neoadjuvant chemotherapy) and postoperative adjuvant chemotherapy and local radiotherapy.